GOLDSTEIN DOV A MD 4

What Happened

• Dov A. Goldstein, MD, Chief Financial Officer of BioAge Labs, exercised stock options (transaction code M) on Feb 1, 2026 to acquire 3,541 shares at an exercise price of $4.38 per share, for a total cash cost of about $15,510. The filing also reports the related derivative (the option) being converted/terminated (reported as a $0 disposal), which is the typical paperwork entry when options are exercised into shares. The Form 4 does not report any sale of the underlying shares on this filing.

Key Details

• Transaction date: 2026-02-01
• Acquired: 3,541 shares at $4.38 each — total ~$15,510 (code M: option exercise)
• Derivative disposed: 3,541 units at $0.00 (conversion/termination of the option)
• Shares owned after transaction: not specified in the provided filing data
• Footnote: Options vest 1/48th monthly, first tranche vested Feb 1, 2025, continuing monthly thereafter, subject to continued service (see F1)
• Filing timeliness: Form filed 2026-02-03 (timely — within the usual two-business-day Form 4 window)

Context

• Code M indicates an option exercise. The separate $0 disposal line represents the option being converted/terminated; it is not a cash sale of shares. Because no sale of the acquired shares is reported here, this transaction primarily documents option exercise rather than a disposition of stock.